October 31, 2006 Presentation: Serum Free Light Chain Assays for the Diagnosis and Monitoring of Multiple Myeloma and Other Monoclonal Gammopathies
Karen van Hoeven, MD, is a board-certified pathologist and technical director with The Binding Site, Inc, developers of the free light chain assays. She completed her residency at Albert Einstein Medical Center in New York, and was fellowship-trained at Memorial Sloan-Kettering Cancer Center and the University of Pennsylvania Medical Center. During her tenure as Assistant Professor of Pathology and Cell Biology at Thomas Jefferson University Hospital in Philadelphia, she authored more than 50 publications in oncology and laboratory medicine. She worked extensively with Millennium Pharmaceuticals on the VELCADE® clinical trial program in multiple myeloma and has worked extensively in the field of hematologic malignancies.